Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Vet Clin Pathol ; 46(1): 158-163, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27935633

RESUMO

A cat with multiple subcutaneous nodules suggesting a soft tissue sarcoma by physical and computed tomographic examination was diagnosed as being affected by subcutaneous filariosis based on cytologic and ultrasonographic assessments. Nodules were surgically removed and extracted nematodes were identified by PCR as Dirofilaria repens. Furthermore, DNA of Dipetalonema dracunculoides (syn. Acantocheilonema dracunculoides) was detected by PCR, with no evidence of circulating microfilariae. To the best of the authors' knowledge, this represents the first report describing adults of D repens in multiple subcutaneous nodules in a cat. Cytopathologic examination allowed characterization of the parasitic nature of the nodules. Veterinary practitioners should be aware of the possible nodular presentation of D repens in cats and should include D repens in the differential diagnosis of subcutaneous neoformations in the cat.


Assuntos
Doenças do Gato/diagnóstico por imagem , Dirofilaria repens/isolamento & purificação , Dirofilariose/diagnóstico por imagem , Animais , Doenças do Gato/parasitologia , Doenças do Gato/patologia , Gatos , Dirofilariose/parasitologia , Dirofilariose/patologia , Feminino , Fibrossarcoma/diagnóstico , Fibrossarcoma/patologia , Fibrossarcoma/veterinária , Microfilárias , Tomografia Computadorizada por Raios X
2.
Ann Ist Super Sanita ; 49(4): 340-6, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24334777

RESUMO

INTRODUCTION: The efficacy of interventions against children malnutrition crucially depends on a myriad of factors other than the simple food intake, that must be carefully studied in order to plan a balanced policy. The relation between dietary patterns and growth is at the very heart of the problem, especially in consideration of the fact that dietary pattern involves dimension other than pure caloric intake in its definition. In this work we investigated the relations between dietary pattern and growth comparing children from a rural and a urban area in Andean Peru, in terms of food habits and anthropometric variables to develop a model usable in context interventions against malnutrition. MATERIAL AND METHODS: A sample of 159 children (80 from urban, 79 from rural area), aged from 4 to 120 months (72.7 ± 37.5 SD) was collected. The data were investigated by a multidimensional (principal component analysis followed by inferential approach) analysis to correlate the different hidden dimensions of both anthropometric and dietary observables. The correlation between these dimensions (in the form of principal components) were computed and contrasted with the effects of age and urban/rural environments. RESULTS: Caloric intake and growth were not linearly correlated in our data set. Moreover urban and rural environment were demonstrated to show very different patterns of both dietary and anthropometric variables pointing to the marked effect of dietary habits and demographic composition of the analyzed populations. The relation between malnutrition and overweight was at the same time demonstrated to follow a strict area-dependent distribution. DISCUSSION AND CONCLUSION: We gave a proof-of-concept of the non-linear character of the relation between malnutrition (in terms of caloric intake) and growth, pointing to the need to calibrate interventions on food pattern and not only quantity to contrast malnutrition effects on growth. The education toward a balanced diet must go hand-in-hand with the intervention on caloric intake in order to prevent effects on health.


Assuntos
Comportamento Alimentar , Crescimento , Antropometria , Criança , Pré-Escolar , Inquéritos sobre Dietas , Feminino , Humanos , Lactente , Masculino , Desnutrição/epidemiologia , Peru/epidemiologia , População Rural , População Urbana
3.
J Alzheimers Dis ; 16(1): 173-80, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19158433

RESUMO

The occurrence of psychotic symptoms is common in Alzheimer's disease (AD), configuring a possibly distinguished clinical entity defined "Psychosis in Alzheimer's Disease" (AD-P). In order to investigate demographic clinical and biological variables potentially associated to the occurrence of AD-P, 148 AD patients were selected. Mini-Mental State Examination (MMSE), Activities of Daily Living (ADL), and Instrumental Activities of Daily Living (IADL) scores, socio-economic status and 5-HTTLPR and APOE gene polymorphisms were determined for each subject. AD-P patients were significantly more frequent carriers of the long (L) allele of 5-HTTLPR. The percentage of AD-P increased with the number of copies of the L-allele: 13% among S homozygote; 36% among heterozygotes; 51% among L-homozygotes. No difference resulted between AD-P and non-psychotic AD (AD-NP) in the distribution of the epsilon4 allele of APOE. The risk of AD-P was increased in L/L homozygous (OR = 7.25, p = 0.003) and, to a lesser extent, in heterozygous (OR = 3.91; p = 0.018). Backward logistic regression analysis showed that the risk for AD-P was increased in older subjects (OR = 1.07; p = 0.018) while an increase of MMSE score was protective (OR = 0.90; p = 0.004). The occurrence of AD-P resulted significantly related to age at examination, cognitive status, and to the presence of the 5-HTTLPR L-allele.


Assuntos
Doença de Alzheimer/genética , Doença de Alzheimer/psicologia , Transtornos Psicóticos/genética , Transtornos Psicóticos/psicologia , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Atividades Cotidianas , Idoso , Alelos , Doença de Alzheimer/epidemiologia , Apolipoproteínas E/genética , Cognição/fisiologia , Educação , Feminino , Genótipo , Humanos , Itália/epidemiologia , Masculino , Estado Civil , Testes Neuropsicológicos , Ocupações , Polimorfismo Genético/genética , Transtornos Psicóticos/epidemiologia
4.
Anticancer Res ; 27(4B): 2523-7, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17695548

RESUMO

BACKGROUND: The aim of this study was to evaluate immunohistochemical markers in pancreatic cancer and to determine the association of their expression with clinicopathological features and prognosis. PATIENTS AND METHODS: Thirty pancreatic adenocarcinoma patients were followed-up for an average period of 5 years. FAS, bcl-2, p53 and Ki-67 expression were detected immunohistochemically to determine their prognostic value. RESULTS: FAS was statistically associated with p53 (p = 0.002), Ki-67 (p = 0.003), higher histological grade (p = 0.001 and recurrence and overall survival (p = 0.001). CONCLUSION: The newly found overexpression of FAS in highly aggressive pancreatic carcinomas may help us stratify patients into different prognostic groups and indicate new therapeutic strategies.


Assuntos
Adenocarcinoma/enzimologia , Ácido Graxo Sintases/biossíntese , Neoplasias Pancreáticas/enzimologia , Adenocarcinoma/patologia , Humanos , Imuno-Histoquímica , Neoplasias Pancreáticas/patologia
5.
Anticancer Res ; 26(4B): 2983-7, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16886624

RESUMO

BACKGROUND: The aim of this study was to detect immunohistochemical markers in breast carcinoma by means of tissue microarray analysis (TMA) and to associate their expressions with clinicopathological features and prognosis. Fatty acid synthase, bcl-2, bcl-x, p53, estrogen and progesterone receptors, heat shock protein 60 and Her2-neu (c-erbB-2) were evaluated in a group of 149 breast carcinoma patients with a 5-year follow-up period. MATERIALS AND METHODS: TMA blocks were made by using duplicate 0.6-mm diameter tissue cores from each paraffin block. RESULTS: Statistical analysis revealed that tumor stage (p=0.003) and node status (p=0.001) were the only two prognostic markers of disease-free survival. Moreover, FAS and bcl-x showed an independent effect on recurrence (p=0.005). The node status was the only marker of overall survival (p=0.05). CONCLUSION: Our data confirmed recent reports associating the stage of disease, FAS and Bcl-x expressions with recurrence and outcome. These data demonstrated that TMA is an effective substitute for conventional histochemical-immunohistochemical techniques.


Assuntos
Neoplasias da Mama/metabolismo , Proteínas de Neoplasias/biossíntese , Neoplasias da Mama/química , Neoplasias da Mama/patologia , Chaperonina 60/análise , Chaperonina 60/biossíntese , Ácido Graxo Sintases/análise , Ácido Graxo Sintases/biossíntese , Seguimentos , Humanos , Imuno-Histoquímica , Proteínas de Neoplasias/análise , Análise Serial de Proteínas , Proteínas Proto-Oncogênicas c-bcl-2/análise , Proteínas Proto-Oncogênicas c-bcl-2/biossíntese , Receptor ErbB-2/análise , Receptor ErbB-2/biossíntese , Receptores de Estrogênio/análise , Receptores de Estrogênio/biossíntese , Receptores de Progesterona/análise , Receptores de Progesterona/biossíntese , Proteína Supressora de Tumor p53/análise , Proteína Supressora de Tumor p53/biossíntese , Proteína bcl-X/análise , Proteína bcl-X/biossíntese
6.
Clin Cancer Res ; 12(8): 2492-7, 2006 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-16638857

RESUMO

Gemcitabine is considered the standard first-line therapy for patients with advanced pancreatic cancer. More recent strategies have focused on improving the efficacy of gemcitabine by either improving the method of delivery or by combining gemcitabine with other non-cross-resistant chemotherapy agents or with small-molecule drugs. However, the clinical benefits, response rates, and duration of responses have been modest. Deoxycytidine kinase (dCK) is the rate-limiting enzyme involved in the metabolism of gemcitabine. The expression of dCK has been postulated to be correlative of gemcitabine resistance. We determined the relationship of dCK immunohistochemical protein expression and/or genetic status of dCK in a panel of human pancreatic cancer tissues and pancreatic cancer cell lines and determined the relationship of these variables to the clinical outcome of patients treated with gemcitabine. We report that dCK protein expression is expressed in the majority of pancreatic cancers analyzed (40 of 44 cases, 91%) and showed a range of labeling intensities ranging from 1+ (labeling weaker in intensity than normal lymphocytes present in same section) to 3+ (labeling greater in intensity than normal lymphocytes present in same section). When labeling intensity was compared with survival, low dCK expression (1+ labeling) was correlated with both overall survival (P < 0.009) and progression-free survival following gemcitabine treatment (P < 0.04). Low dCK labeling intensity was also significantly correlated with patient age (70.3 +/- 8.1 versus 59.8 +/- 7.4 years; P < 0.0006), suggesting that age-related methylation of the dCK gene may account in part for the observed differences. Sequencing of the entire dCK coding sequence in 17 cell lines and 9 patients' cancer tissues with disease progression while on gemcitabine did not identify any mutations, suggesting that genetic alterations of dCK are not a common mechanism of resistance to gemcitabine for this tumor type. Moreover, dCK labeling showed similar patterns and intensities of labeling among matched pretreatment and post-treatment tissues. In summary, pretreatment levels of dCK protein are most correlated with overall survival following gemcitabine treatment and are stable even after resistance to gemcitabine is clinically documented.


Assuntos
Desoxicitidina Quinase/metabolismo , Neoplasias Pancreáticas/patologia , Antimetabólitos Antineoplásicos/farmacologia , Antimetabólitos Antineoplásicos/uso terapêutico , Linhagem Celular Tumoral , Metilação de DNA , Análise Mutacional de DNA , DNA de Neoplasias/química , DNA de Neoplasias/genética , DNA de Neoplasias/metabolismo , Desoxicitidina/análogos & derivados , Desoxicitidina/farmacologia , Desoxicitidina/uso terapêutico , Desoxicitidina Quinase/genética , Resistência a Medicamentos/genética , Feminino , Humanos , Imuno-Histoquímica , Masculino , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/enzimologia , Análise de Sobrevida , Gencitabina
7.
Cancer Biol Ther ; 4(12): 1381-6, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16319527

RESUMO

The Epidermal Growth Factor Receptor (EGFR) plays a role in multiple tumor cell processes and is targeted by several anticancer therapies. Although EGFR mutations may determine tumor susceptibility in a small proportion of patients, knowledge of the EGFR signaling pathway status in tumors may help guide further drug development and hypothesis-driven combination studies. We aimed to validate and apply a novel computer-aided immunohistochemical (IHC) technique to characterize the status of EGFR signaling in matched colorectal tumor and normal colon tissue samples. Tissue Microarrays (TMA)were made from both cancerous and normal colorectal tissue in 18 patients and stained with antibodies against EGFR, phospho-EGFR (pEGFR), Akt, pAkt, MAPK, and pMAPK. TMA's were quantitatively scored using the Automated Cellular Imaging System (ACIS II, Chromavision, Inc). ACIS was compared against cell line Western blotting, ELISA, and visual scoring (0-3+) by a pathologist. We found that ACIS analysis was highly reproducible and results were well correlated with other techniques. A post-scan "image microdissection" technique of analyzing heterogeneous human samples showed good correlation between paired human samples [Pearson correlation for tumors, 0.922 (p < .001)]. Cancer samples had markedly higher staining of pEGFR, Akt, pAkt, MAPK, and pMAPK. We conclude that ACIS IHC of human tissue samples is quantitative, reproducible, and correlates with Western blots and ELISA in cell line pellets as well as pathologist's scores of human samples. Colorectal tumors show higher staining of pEGFR and downstream effectors compared to matched normal colorectal tissues.


Assuntos
Colo/química , Neoplasias Colorretais/química , Receptores ErbB/análise , Processamento de Imagem Assistida por Computador/métodos , Transdução de Sinais , Ensaio de Imunoadsorção Enzimática , Receptores ErbB/genética , Estudos de Avaliação como Assunto , Humanos , Processamento de Imagem Assistida por Computador/instrumentação , Immunoblotting , Imuno-Histoquímica , Reprodutibilidade dos Testes
8.
Int J Gynecol Pathol ; 24(4): 404-8, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16175090

RESUMO

We explored the immunohistochemical expression of fatty acid synthase (FAS) in Paget's disease of the vulva (PDV) and its association with clinico-pathological features. FAS is a recently discovered molecule involved in energy supply of normal cells. FAS is also overexpressed in neoplastic tissues because of their increased necessity of energy. Specimens from 20 patients with PDV were immunohistochemically evaluated; increased FAS expression was observed in 7 of 8 patients with invasive PDV (87%), in 3 of 4 patients with microinvasive PDV (75%), and in 1 of 8 patients with noninvasive PDV (12%). Statistical analysis revealed that increased FAS expression was associated with invasive PDV (p = 0.04). To our knowledge, this association of FAS in PDV is the first to be reported in literature. These observations reveal that FAS is a reliable marker of aggressiveness in PDV. The knowledge of FAS statistical association in invasive PDV is an important finding that may stratify these patients in different prognostic groups and determine therapeutic approaches for patient care.


Assuntos
Ácido Graxo Sintases/análise , Doença de Paget Extramamária/enzimologia , Neoplasias Vulvares/enzimologia , Idoso , Idoso de 80 Anos ou mais , Citoplasma/enzimologia , Feminino , Humanos , Imuno-Histoquímica , Invasividade Neoplásica , Doença de Paget Extramamária/patologia , Neoplasias Vulvares/patologia
9.
Cancer Res ; 65(8): 3003-10, 2005 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-15833824

RESUMO

Analysis of gene expression of cancer cell lines exposed to erlotinib, a small molecule inhibitor of the epidermal growth factor receptor (EGFR), showed a marked increase in EGFR mRNA in resistant cell lines but not in susceptible ones. Because cetuximab induces EGFR down-regulation, we explored the hypothesis that treatment with cetuximab would interfere with erlotinib-induced EGFR up-regulation and result in antitumor effects. Exposure of the resistant biliary tract cancer cell line HuCCT1 but not the susceptible A431 epidermoid cell line to erlotinib induced EGFR mRNA and protein expression. Combined treatment with cetuximab blunted the erlotinib-induced EGFR up-regulation and resulted in inhibition of cell proliferation and apoptosis in the HuCCT1 cells. Blockage of erlotinib-induced EGFR synthesis in HuCCT1 cells by small interfering RNA resulted in identical antitumor effects as cetuximab, providing mechanistic specificity. In mice xenografted with A431, HuCCT1, and the pancreatic cancer cell line Panc430, maximal growth arrest and decrease in Ki67 proliferation index were documented with combined therapy, and EGFR down-regulation was observed in cetuximab-treated tumors. These results may indicate that resistance to EGFR kinase inhibition may be, at least in part, mediated by a highly dynamic feedback loop consisting of up-regulation of the EGFR upon exposure to EGFR kinase inhibitors. Abrogation of this response by small interfering RNA-mediated EGFR mRNA down-regulation and/or by cetuximab-mediated protein clearance induced tumor arrest across several cancer models with different EGFR expression levels, suggesting that resistance and sensitivity are dynamic events where proportional decrease in the target rather than absolute content dictates outcome.


Assuntos
Anticorpos Monoclonais/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Receptores ErbB/antagonistas & inibidores , Quinazolinas/farmacologia , Animais , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Humanizados , Neoplasias do Sistema Biliar/tratamento farmacológico , Neoplasias do Sistema Biliar/enzimologia , Neoplasias do Sistema Biliar/genética , Linhagem Celular Tumoral , Cetuximab , Colangiocarcinoma/tratamento farmacológico , Colangiocarcinoma/enzimologia , Colangiocarcinoma/genética , Receptores ErbB/biossíntese , Receptores ErbB/genética , Cloridrato de Erlotinib , Feminino , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Inativação Gênica , Humanos , Imuno-Histoquímica , Camundongos , Camundongos Nus , Inibidores de Proteínas Quinases/farmacologia , Quinazolinas/administração & dosagem , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , RNA Interferente Pequeno/genética , Transfecção
10.
Gynecol Oncol ; 92(1): 101-5, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14751145

RESUMO

PURPOSE: To explore the expression of fatty acid synthase (FAS) and human erythrocyte glucose transporter 1 (GLUT1) in endometrial carcinomas and to detect associations with clinicopathological features and prognosis. FAS and GLUT1 are two molecules involved in energy supply of normal cells. These markers are overexpressed in neoplastic tissues because of their increased necessity of energy. METHODS: Ninety-five patients with endometrial carcinoma were followed-up for an average period of 5 years. FAS and GLUT1 expressions were evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tissues. Staining was determined with a semiquantitative method. Negative controls were obtained from patients submitted to hysterectomy for uterine prolapse. RESULTS: Eighty-five cases were endometrioid, 7 were serous, and 1 was a mucinous carcinoma. Seventy-two cases (75%) were stage I, 12 (13%) were stage II, and 11 (12%) were stage III carcinomas. Sixteen (15%) carcinomas recurred. Nine patients (8%) died for cancer during the follow-up period. FAS expression was observed in 53 cases (56%). GLUT1 expression was observed in 32 (43%) cases. Statistical analysis revealed that FAS (P = 0.04) and stage (P = 0.001) of the disease were the only two independent predictors of recurrence. GLUT1 and other clinicopathologic parameters had no prognostic association. CONCLUSIONS: FAS is a reliable marker of clinically aggressive endometrial carcinomas. The knowledge of FAS expression in endometrial carcinomas is an important finding that may stratify patients into selected groups and determine therapeutic approaches for patient care.


Assuntos
Biomarcadores Tumorais/biossíntese , Neoplasias do Endométrio/enzimologia , Ácido Graxo Sintases/biossíntese , Recidiva Local de Neoplasia/enzimologia , Neoplasias do Endométrio/metabolismo , Neoplasias do Endométrio/patologia , Neoplasias do Endométrio/cirurgia , Feminino , Seguimentos , Transportador de Glucose Tipo 1 , Humanos , Imuno-Histoquímica , Pessoa de Meia-Idade , Proteínas de Transporte de Monossacarídeos/biossíntese , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Prognóstico
11.
Anticancer Res ; 24(6): 4169-73, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15736468

RESUMO

BACKGROUND: We explored the expression of Fatty Acid Synthase (FAS) in lung carcinomas and its association with clinico-pathological features and prognosis. FAS is a recently discovered molecule involved in the energy supply of normal cells. FAS is also overexpressed in neoplastic tissues because of their increased necessity for energy. PATIENTS AND METHODS: One hundred and six patients with non-small cell lung carcinoma were followed-up for an average period of 5 years. FAS expression was detected immunohistochemically. RESULTS: FAS staining was observed in 61 out of 106 cases (57.54%). Statistical analysis revealed that FAS had an overall low prognostic value (p = 0.14), while FAS-negative expression in stage I patients showed a trend for better survival (p = 0.10). PTNM stage (p < 0.0001) was the only significant prognostic marker for overall survival. CONCLUSION: FAS is a reliable marker of low-stage clinically aggressive lung carcinomas. The determination of FAS expression in lung carcinomas may stratify patients and determine therapeutic approaches for their care.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/enzimologia , Ácido Graxo Sintases/metabolismo , Neoplasias Pulmonares/enzimologia , Recidiva Local de Neoplasia/enzimologia , Idoso , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/cirurgia , Feminino , Humanos , Imuno-Histoquímica , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/cirurgia , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Fatores de Risco
12.
Anticancer Res ; 23(1A): 335-9, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12680233

RESUMO

BACKGROUND: Fatty Acid Synthase (FAS) and Human Erythrocyte Glucose Transporter 1 (GLUT1) are new markers involved in the biological activities of cancer cells. FAS is a multifunctional enzyme that synthesizes palmitate from acetyl-CoA and malonyl-CoA. GLUT1 is a transmembrane protein normally expressed in perineurium and erythrocytes. FAS and GLUT1 expression have been recently described in many aggressive tumors. We explored the immunohistochemical expression of FAS and GLUT1 in bladder carcinomas to reveal statistical associations with clinico-pathological features and recurrence. MATERIALS AND METHODS: Thirty-one node- and distant metastasis-negative transitional cell carcinomas from patients with a five-year follow-up were evaluated for FAS and GLUT1 expression. RESULTS: Univariate analysis showed that low-grade, pTa stage and FAS-negative expression were associated with indolent tumors. Multivariate analysis showed that FAS expression (p = 0.006) and pT1-2 stage tumors (p = 0.001) were independent predictors of recurrence. CONCLUSION: Endogenous fatty acids are an exploitable storage of energy for aggressive human bladder carcinomas. Glucose uptake is not required by bladder tumors.


Assuntos
Carcinoma de Células de Transição/metabolismo , Ácido Graxo Sintases/biossíntese , Proteínas de Transporte de Monossacarídeos/biossíntese , Neoplasias da Bexiga Urinária/metabolismo , Análise de Variância , Carcinoma de Células de Transição/enzimologia , Carcinoma de Células de Transição/cirurgia , Cistectomia , Transportador de Glucose Tipo 1 , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/enzimologia , Recidiva Local de Neoplasia/metabolismo , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Neoplasias da Bexiga Urinária/enzimologia , Neoplasias da Bexiga Urinária/patologia , Neoplasias da Bexiga Urinária/cirurgia
13.
Ann Diagn Pathol ; 6(4): 229-35, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12170454

RESUMO

Primary hyperparathyroidism is the clinical result of parathyroid adenoma or hyperplasia, rarely of carcinoma. Clinical, serologic, and radiologic data are unable to discriminate a single parathyroid adenoma from an enlarged hyperplastic gland. Morphologic features also overlap in adenoma and small hyperplastic gland. Studying immunohistochemical expression of fatty acid synthase (FAS), p53, Ki67 and bcl-2, we found that among 21 adenomas 19 (90.5%) were positive for FAS, 12 (57.2%) for Ki67, 11 (52.4%) for p53, and 16 (76.2%) for bcl-2; among 12 hyperplasias, 12 (100%) were positive for FAS, 6 (50%) for KI67, 8 (66.7%) for p53, and 8 (66.7%) for bcl-2. Statistical analysis showed that FAS was associated with parathormone (PTH) (P =.001), Ki67 (P =.01), and p53 (P =.01). Moreover, FAS was associated with hyperplastic (P =.0001) and adenomatous glands (P =.0001). Ki67 was associated with both adenomatous (P =.02) and hyperplastic glands (P =.005). P53 protein were associated only with hyperplastic glands (P =.01). The different occurrence of p53 in parathyroids adenoma and hyperplasia may enable a different management and follow-up of the patients with primary hyperparathyroidism, stratifing them into two groups. The first, with a "false" adenoma having a high risk of relapse, may necessitate exams like serum calcium levels, PTH concentrations, urinary calcium levels for 24 hours, kidney functional tests, and radiology and ultrasound every 3 to 6 months, whereas the second with "true" adenoma, at low risk of relapse, may be checked less frequently with serum calcium levels and PTH concentrations.


Assuntos
Adenoma/patologia , Biomarcadores Tumorais/análise , Glândulas Paratireoides/patologia , Neoplasias das Paratireoides/patologia , Proteína Supressora de Tumor p53/análise , Adenoma/complicações , Adulto , Idoso , Proteínas Reguladoras de Apoptose , Proteínas de Transporte/análise , Diagnóstico Diferencial , Ácido Graxo Sintases/análise , Feminino , Humanos , Hiperparatireoidismo/etiologia , Hiperplasia/complicações , Hiperplasia/patologia , Técnicas Imunoenzimáticas , Antígeno Ki-67/análise , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Neoplasias das Paratireoides/complicações
14.
Anticancer Res ; 22(5): 2671-5, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12529980

RESUMO

UNLABELLED: The purpose of this study was to clarify the role and the predictive strength of the adhesion molecule CD44s (standard isoform) in colorectal carcinogenesis. MATERIALS AND METHODS: CD44s immunohistochemical expression was evaluated in 100 patients with colon adenoma and 100 patients with colon adenocarcinoma and adjacent non-neoplastic mucosa (ANNM). The patients were followed-up for five years. RESULTS: CD44s immunoreactivity was expressed in low-moderate-high-grade dysplasia adenomas and associated with adenocarcinoma (p = 0.01), ANNM (p = 0.05) and pTNM stage (p = 0.00001). Univariate analysis revealed that CD44s expression was associated with overall survival (OS) in carcinomas (p = 0.01) and ANNM (p = 0.05). Bivariate analysis revealed that CD44s was associated with OS in stages I and II patients (p = 0.03). Multivariate analysis revealed that stage (p = 0.0001) and CD44s expression (p = 0.05) were independent predictors of OS. CONCLUSION: CD44s is involved in colon carcinogenesis and is associated with aggressive carcinomas. The immunohistochemical expression of CD44s may reveal cells that have lost their adhesion ability and therefore detect carcinomas with high metastatic power.


Assuntos
Adenocarcinoma/metabolismo , Adenoma/metabolismo , Neoplasias Colorretais/metabolismo , Receptores de Hialuronatos/biossíntese , Adenocarcinoma/imunologia , Adenocarcinoma/patologia , Adenoma/imunologia , Adenoma/patologia , Neoplasias Colorretais/imunologia , Neoplasias Colorretais/patologia , Células Epiteliais/imunologia , Células Epiteliais/metabolismo , Feminino , Humanos , Receptores de Hialuronatos/imunologia , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estadiamento de Neoplasias , Prognóstico , Isoformas de Proteínas , Análise de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA